TXMD TherapeuticsMD Inc.

3.18
-0.08  -2%
Previous Close 3.26
Open 3.25
Price To Book 12.72
Market Cap 767085451
Shares 241,221,840
Volume 2,799,227
Short Ratio
Av. Daily Volume 2,985,335

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced October 29, 2018.
TX-001HR: BIJUVA
Moderate to severe vasomotor symptoms (VMS)
CRL announced May 8, 2017. NDA resubmitted with approval announced May 30, 2018.
Yuvvexy - TX-004HR
Moderate-to-severe vaginal pain
FDA Approval announced August 10, 2018.
Segesterone Acetate/ Ethinyl Estradiol
Contraception

Latest News

  1. Edited Transcript of TXMD earnings conference call or presentation 6-May-19 8:30pm GMT
  2. TherapeuticsMD Announces Participation at the Bank of America Merrill Lynch 2019 Health Care Conference
  3. Here's Why TherapeuticsMD Fell as Much as 17.6% Today
  4. See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
  5. TherapeuticsMD Inc (TXMD) Q1 2019 Earnings Call Transcript
  6. TherapeuticsMD (TXMD) Reports Q1 Loss, Misses Revenue Estimates
  7. TherapeuticsMD: 1Q Earnings Snapshot
  8. TherapeuticsMD Announces First Quarter 2019 Financial Results
  9. Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
  10. TherapeuticsMD Presented New Research at the American College of Obstetricians and Gynecologists 2019 Annual Meeting that Explores How Women’s Menopausal Symptoms Affect Men
  11. Is TherapeuticsMD Inc (TXMD) A Good Stock To Buy?
  12. TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the American College of Obstetricians and Gynecologists 2019 Annual Meeting
  13. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating TherapeuticsMD, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  14. TherapeuticsMD to Report First Quarter 2019 Results on May 6, 2019
  15. Analysts Estimate TherapeuticsMD (TXMD) to Report a Decline in Earnings: What to Look Out for
  16. TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
  17. TherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
  18. TherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.
  19. Is TherapeuticsMD, Inc. (NASDAQ:TXMD) Overpaying Its CEO?